- Report
- February 2021
- 158 Pages
North America
From €2002EUR$2,100USD£1,717GBP
€2859EUR$3,000USD£2,453GBP
- Report
- January 2021
Global
From €3036EUR$3,185USD£2,604GBP
€4337EUR$4,550USD£3,720GBP
- Report
- August 2020
- 85 Pages
North America
From €4527EUR$4,750USD£3,884GBP
- Report
- February 2023
- 206 Pages
Global
From €3036EUR$3,185USD£2,604GBP
€4337EUR$4,550USD£3,720GBP
- Report
- March 2021
- 270 Pages
Global
From €3431EUR$3,600USD£2,943GBP
- Drug Pipelines
- April 2023
- 34 Pages
Global
From €9526EUR$9,995USD£8,172GBP
- Drug Pipelines
- April 2023
- 34 Pages
Global
From €9526EUR$9,995USD£8,172GBP
- Report
- May 2023
- 147 Pages
Global
From €5718EUR$5,999USD£4,905GBP
- Report
- May 2023
- 147 Pages
Global
From €5718EUR$5,999USD£4,905GBP
Allogeneic cell therapy is a type of genomics-based therapy that uses cells from a donor to treat a patient. It is a form of immunotherapy that uses cells from a healthy donor to stimulate the patient's immune system to fight disease. Allogeneic cell therapy is used to treat a variety of conditions, including cancer, autoimmune diseases, and genetic disorders. It is also being explored as a potential treatment for neurological disorders.
Allogeneic cell therapy is a rapidly growing field, with many companies developing new treatments and technologies. Examples of companies in the allogeneic cell therapy market include Kite Pharma, Juno Therapeutics, and Bellicum Pharmaceuticals. Other companies, such as Cellectis and Fate Therapeutics, are also researching and developing allogeneic cell therapies. Show Less Read more